Extraordinary radiation super-sensitivity accompanying with sorafenib combination therapy: what lies beneath? |
Lee, Jayoung
(Department of Radiation Oncology, Pusan National University Yangsan Hospital)
Lee, Ju Hye (Department of Radiation Oncology, Pusan National University Yangsan Hospital) Yoon, Hanbin (Department of Radiation Oncology, Pusan National University Yangsan Hospital) Lee, Ho Jeong (Department of Radiation Oncology, Pusan National University Yangsan Hospital) Jeon, Hosang (Department of Radiation Oncology, Pusan National University Yangsan Hospital) Nam, Jiho (Department of Radiation Oncology, Pusan National University Yangsan Hospital) |
1 | Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol 2013;47 Suppl:S2-6. DOI |
2 | Raza A, Sood GK. Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J Gastroenterol 2014;20:4115-27. DOI |
3 | Ohri N, Dawson LA, Krishnan S, et al. Radiotherapy for hepatocellular carcinoma: new indications and directions for future study. J Natl Cancer Inst 2016;108;djw133. DOI |
4 | McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis 2011;15:223-43, vii-x. |
5 | Brade AM, Ng S, Brierley J, et al. Phase 1 Trial of sorafenib and stereotactic body radiation therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2016;94:580-7. DOI |
6 | Chen SW, Lin LC, Kuo YC, Liang JA, Kuo CC, Chiou JF. Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2014;88:1041-7. DOI |
![]() |